Lineage Cell Therapeutics, Inc. BTX Cash Flow

Lineage cell therapeutics, inc. (BTX)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS)/INCOME ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.
-8,399	-4,482	-16,505	-30,032	39,310	-44,952	66,725	-4,215	-63,548	-71,934	14,321	-11,651	49,288	-5,075	31,209	24,550	-17,112	-13,424	-13,702	-9,698	-10,167	-10,584	-8,219	-9,509	-8,099	-19,612	-8,988	-7,563	-7,719	-6,034	-4,961	-5,455	-4,973	-5,360	-3,512	-4,280	-3,362
Net loss attributable to noncontrolling interest
-29	-74	-10	-20	-14	-32	-181	-431	-150	-138	-335	-576	-2,264	-2,665	-2,195	-3,206	-6,885	-3,381	-3,026	-7,159	2,423	-2,216	-1,655	-5,125	1,629	-6,442	-1,237	-657	-689	-1,116	-966	-535	-1,260	-94	-531	-719	-582
Adjustments to reconcile net (loss) income attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Gain on sale of marketable equity securities
1,258	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of shares and deconsolidation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equity method investment in Ascendance
-	-	-	-	-	-	-	-	3,215	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	0	0	0	800	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on equity method investment in Asterias at fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on equity method investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on marketable equity securities
-1,338	236	-4,458	-607	1,931	523	23	397	215	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	3,877	-	-	-	0	-1,121	-947	-1,271	-1,177	-2,201	-2,313	-1,512	-1,349	-3,281	0	0	0	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	4,384	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense, including amortization of leasehold improvements
212	236	253	244	269	267	254	279	281	277	249	205	216	184	248	319	429	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of right-of-use asset
9	70	32	13	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	264	249	263	-	271	266	256	237	166	139	113	102	99	95	88	112	132	62	65
Amortization of intangible assets
498	498	508	507	485	477	551	582	582	583	582	582	602	642	643	978	1,314	1,314	1,314	1,314	1,314	3,256	1,368	1,368	1,367	1,368	642	642	642	682	640	587	535	364	584	585	456
Amortization of deferred license and royalty revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-65
Amortization of deferred consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2	16	16	16	16	16	16	194	194	194	16	194	194	194
Amortization of deferred license fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30	28	27	28	27	27	27	-	-	-	-	-	-	59	27	-	-	27	27
Amortization of deferred license, royalty and subscription revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Amortization of deferred license fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-790	-48	-32	-42	-98	-36	-37	-38	-	-	-	-
Amortization of prepaid rent in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	21	21	43	0	20	21	85	0	0	0	-	-	-	-	-	-	-	-
Stock-based compensation
626	619	759	762	1,440	2,005	1,310	1,103	984	1,029	973	904	1,026	1,648	710	2,220	3,373	-	-	-	1,914	1,134	1,109	1,410	801	842	1,023	659	691	402	511	613	316	974	268	270	289
Change in unrealized gain on warrant liability
-35	-	-	-	-37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of liability classified warrants
-	-	-	-	-	-	-	-459	108	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liability classified warrants
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write-off of expired inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-2	4
Options issued as independent director compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	157	-	141	142	143
Loss/(gain) on sale or write-off of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	12	8	0	-5	-0	1	14	1	3	0	-	-	-	-
Subsidiary shareholder expense for subsidiary warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Subsidiary common stock issued in lieu of cash for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	486	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in receivables from the reversal of revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-0	-0	-204	0	0	0	0
Amortization of deferred license fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27	27	27	-	-	-	-	-	-	-	-
Amortization of deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	-2	-2	-	-2	-5	0	38	0	2	29
Amortization of discount on related party convertible debt
-	-	-	-	-	-	-	-	-	0	0	387	253	184	19	180	65	63	63	69	50	52	4	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency remeasurement and other (gain) loss
-1,424	456	450	622	839	-895	349	-1,050	-87	781	-834	2,643	-829	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BioTimes share of losses and impairment of Ascendance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-35	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency remeasurement and other (gain) loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,449	81	-536	-347	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9	-11	11	-36	62	-0	-185	-9	-6	-33	-7	-9	-3	-3	-9	-7	1	-27	-5
Deferred grant income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-243	-	-	456	1,474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts and grants receivable, net
-66	167	-1,497	249	614	61	-975	831	37	-733	1,204	-51	-248	-1,142	901	18	36	178	-29	102	-171	-12	49	12	24	114	40	-57	82	-495	447	15	-3	95	-96	3	118
Accrued interest receivable
378	2,646	-378	-1,134	378	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables from OncoCyte and AgeX, net of payables
40	-157	237	-56	-2,129	-73	-306	-5	-175	-397	-428	-563	231	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-81	181	-30	32	-93	92	-57	-	-	-	-	-	-	-	-	-	-	-0	-22
Receivables from affiliates, net of payables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55	-199	335	-202	372	-1,202	641	-371	1,001	-225	-359	0	-5	5	0	-261
Inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-36	-3	33	12	-4	21	57	117	-3	12	-2	-1	1	0	3	-9	4	-16	-9
Prepaid expenses and other current assets
-911	124	135	-65	66	-271	449	46	213	-52	12	233	-338	102	617	137	259	912	320	240	61	-28	-201	-60	375	-143	-699	170	243	368	-133	109	-116	383	448	-441	313
Accounts payable and accrued liabilities
-138	-97	-1,984	-563	-241	1,414	22	504	-840	23	435	186	655	-387	610	-1,668	1,457	1,161	1,322	-445	-365	1,075	490	-758	-1,276	1,964	208	70	-101	1,605	-325	701	-1,074	931	-470	506	-367
Deferred revenue and other liabilities
167	-	-	-	-	61	-134	-116	46	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	-	-	-	-	-	-147	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest on related party convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-3	-1	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-63	-59	-1	62	-75	4	4	5	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174	-112	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-5,026	-5,523	-7,443	-9,667	-9,314	-5,812	-7,332	-7,400	-10,338	-5,675	-7,681	-9,063	-8,098	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,021	-	-5,008	-3,957	-5,716	-3,845	-3,595	-2,795	-3,357
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment and other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	476	801	583	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash equivalents in escrow
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-815	815	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and cash equivalents acquired in the Asterias Merger
-	0	0	0	3,117	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of license fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1
Purchase of equipment and other assets
10	7	69	195	169	157	162	39	198	396	456	259	215	-	-	-	-	-	-	-	77	-14	92	173	231	300	1,240	238	496	195	51	36	116	179	242	242	295
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14,313	-	-11,561	-9,967	-9,069	-9,110	-8,609	-10,777	-10,357	-	-	-	-	-	-	-	-	-	-	-	-
Deconsolidation of cash and cash equivalents of AgeX
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the sale of equity method investment in Ascendance
-	-	-	-	-	0	0	0	3,215	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of in-process research and development by AgeX
-	-	-	-	-	0	1,072	0	800	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on construction in progress
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	11	267	263	1,312	2,222	296	219	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Security deposit paid and other
-45	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid, net of cash acquired for CTI assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	246
Cash acquired in connection with merger with Glycosan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	5
Proceeds from sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	0	0	4	0	30	0	0	-	-	-	-	-	-	-	-
Security deposit paid and other
-	-	-	-	-	-	-	-2	-6	-	-	29	-41	-	-	-	-	-	-	-	-	-9	0	-6	-299	-3	-7	0	-54	-0	-0	0	-0	-0	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
5,256	720	13,485	-194	2,946	9,784	-138	-41	2,211	-583	-258	-230	-9,154	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-550	-	-51	260	-117	-179	-242	-242	-537
CASH FLOWS FROM FINANCING ACTIVITIES:
Fees paid on sale of common shares
-	-	-	-	-	-	-	-	-	2,175	-46	324	1,345	0	204	1,311	0	-	-	-	-	25	-4	89	212	69	0	428	319	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-4	0	4	25	-2,015	0	1,966	49	0	0	274	347	-1	0	161	58	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options from employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	7	72
Proceeds from the exercise of stock options from directors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	97	14
Proceeds from the exercise of stock options from outside consultant
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2	2
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	8	30	386
Common shares received and retired for employee taxes paid
2	9	24	3	74	177	13	6	7	7	7	31	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement from landlord on tenant improvements
-	14	6	6	738	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of subsidiary common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-171	6	165	-	-	-	-	0	0	468	0	4,999	0	125	130	250	0	0	0	0	3,000	0	213
Cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,665	-	-2,027	-2,453	-373	-209	-92	-179	-527	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,500	0	0	0	0	-	-	-	-	-	-	-	-
Repayment of capital lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	-14	-	-13	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Employee options exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from exercise of director stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Financing fees paid upon issuance of common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Net proceeds from sale of common shares
-	-	-	-	-	-	-	-	-	28,750	0	0	20,125	0	2,625	17,500	0	26,892	-3,008	6,086	5,500	29,426	0	6,541	8,182	2,128	0	12,111	11,699	1,131	0	0	0	-	-	-	-
Proceeds from sale of subsidiary warrants
-	-	-	-	-	-	-	0	737	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of financing lease liabilities
8	10	6	8	6	93	4	54	97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of subsidiary warrants
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of lease liability and capital lease obligation
-	-	-	-	-	-	-	-	-	173	0	0	31	41	30	57	17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fees paid on sale of subsidiary common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	164	433	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement from landlord on construction in progress
-	-	-	-	-	-	-	-	-	0	0	-2	200	116	40	-156	567	1,225	2,004	276	284	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of related party convertible debt
-	-	-	-	-	-	-	-	-	41	85	176	123	607	131	1,019	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of principal portion of promissory notes
-	0	0	18	52	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of treasury shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-13,582	12,982	599	-1,819	0	216	1,602	282	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	764	-	11,159	18,388	5,684	30,973	458	20,063	12,128	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used by) provided by financing activities
-10	-5	79	-63	606	94	145	4,902	633	26,379	4,992	4,923	19,097	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,113	-	271	14	0	0	3,034	137	689
Effect of exchange rate changes on cash, cash equivalents and restricted cash
73	-58	45	30	53	46	-19	-81	60	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-41	204	-117	55	-80	200	117	-158	342	-333	101	416	-63	-21	-101	-62	45	68	5	84	-40	-145	110	6	-347	145	17
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
293	-4,866	6,166	-9,894	-5,709	4,112	-7,344	-2,620	-7,434	20,176	-2,988	-4,166	1,728	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
-	-	-	-	-	-	-	-	-	-	-	-	-	-8,363	2,749	570	-15,097	12,851	-2,087	5,635	-3,657	22,070	-8,306	9,084	1,142	-1,221	-7,588	4,409	5,546	-3,480	-4,829	-3,828	-5,723	-4,018	-1,151	-2,755	-3,187
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0	0	0	0	0	0	0	-0	0	0	0
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Common shares issued for consulting services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	24	71	77	0	0	0	0	-	-	-	-
Common shares issued for rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	11	0	242	0	0	0	0	-	-	-	-
Common shares issued in connection with the purchase of assets from CTI
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,300
Common shares issued as part of merger with Glycosan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,600
Warrants issued as part of merger with Glycosan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	954
OncoCyte Corporation [Member]
Unrealized gain on equity method investment
-	-	-	-	37,713	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on equity method investment
-	-	-	-	-	-	-	6,603	-37,419	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the sale of common shares
4,963	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asterias Biotherapeutics [Member]
Unrealized gain on equity method investment
-	-	-	-	6,744	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on equity method investment
-	-	-	-	-	-	-	-2,175	-17,398	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
AgeX Therapeutics, Inc. [Member]
Proceeds from the sale of common shares
258	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-